SURPASS-CVOT is the first head-to-head Phase 3 cardiovascular outcomes trial comparing two incretin therapies in adults with type 2 diabetes and established atherosclerotic cardiovascular disease. It was conducted in 30 countries spread over more than 4 years.The trial evaluated Mounjaro (tirzepatide), a dual GIP/GLP-1 receptor agonist, against Trulicity (dulaglutide), a GLP-1 receptor agonist previously shown to offer cardiovascular benefits in the REWIND study.
Mounjaro met the trial's primary endpoint by demonstrating non-inferiority to Trulicity in reducing major adverse cardiovascular events (MACE-3), including cardiovascular death, myocardial infarction, or stroke. Although not adjusted for multiplicity, Mounjaro also showed additional benefits, including improved A1C levels, greater weight loss, better renal function, and reduced all-cause mortality.
Cardiovascular disease remains the leading cause of death among people living with type 2 diabetes," said Kenneth Custer, Ph.D., executive vice president and president, Lilly Cardiometabolic Health. "The SURPASS-CVOT results show that Mounjaro preserved the cardioprotective benefit of Trulicity, a GLP-1 receptor agonist, while providing additional benefits, including greater kidney protection and a reduced overall risk of death. These findings strengthen the case for Mounjaro as a potential front-line treatment for people with type 2 diabetes and cardiovascular disease."
Complete findings from the SURPASS-CVOT trial will be presented at the European Association for the Study of Diabetes (EASD) annual meeting in September 2025 and subsequently published in a peer-reviewed journal.
Meanwhile, tirzepatide is also being evaluated in another large-scale cardiovascular outcomes trial, SURMOUNT-MMO. This study is assessing whether the drug can reduce the risk of all-cause mortality, nonfatal myocardial infarction, nonfatal stroke, coronary revascularization, or heart failure events in individuals with overweight and either established cardiovascular disease or multiple age-related risk factors. Results from SURMOUNT-MMO are expected in 2027.
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.